Drugmaker Cipla Ltd. has announced an 18% year-on-year increase in net profit, reaching ₹1,177.64 crore for the latest quarter. In the same period last year, Cipla reported a profit of ₹995.7 crore.
The company’s revenue from operations was ₹6,693.94 crore, slightly below the estimate of ₹6,774.6 crore but up 6% from ₹6,329 crore in the previous year. Cipla’s EBITDA, which excludes interest, tax, depreciation, and amortization, grew 15% year-on-year to ₹1,715.9 crore, compared to ₹1,493.9 crore a year earlier. The EBITDA margin was 25.6%, surpassing expectations of 23.8%.
Cipla achieved its highest-ever quarterly sales in North America at $250 million, driven by strong performance in its differentiated portfolio. The company’s India business saw a 10% growth year-on-year, although the Trade Generics Business experienced some softness due to changes in the distribution model.
With a net cash position of ₹8,449 crore, Cipla’s debt mainly consists of lease liabilities and working capital needs. Looking forward, Cipla aims to enhance growth in key markets, strengthen flagship brands, invest in its future pipeline, and address regulatory issues.
Following the earnings announcement, Cipla’s stock surged nearly 6% on the NSE, reaching a day’s high of ₹1,600.
